Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:RLMD NASDAQ:SPRO NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.36+0.9%$4.39$1.34▼$5.15$608.92M0.761.89 million shs1.68 million shsRLMDRelmada Therapeutics$6.37-4.2%$7.03$0.52▼$8.00$668.15M0.391.38 million shs3.07 million shsSPROSpero Therapeutics$2.91+2.1%$2.69$1.80▼$3.22$168.49M1.45465,983 shs931,447 shsTLRYTilray Brands$5.01+0.6%$5.94$3.51▼$23.20$583.92M1.884.34 million shs3.77 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%-0.92%-4.42%+15.51%+193.88%RLMDRelmada Therapeutics0.00%+11.76%-3.62%+7.61%+849.73%SPROSpero Therapeutics0.00%+1.06%+2.15%+10.04%+0.71%TLRYTilray Brands0.00%+0.81%-6.39%-27.83%+23.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.36+0.9%$4.39$1.34▼$5.15$608.92M0.761.89 million shs1.68 million shsRLMDRelmada Therapeutics$6.37-4.2%$7.03$0.52▼$8.00$668.15M0.391.38 million shs3.07 million shsSPROSpero Therapeutics$2.91+2.1%$2.69$1.80▼$3.22$168.49M1.45465,983 shs931,447 shsTLRYTilray Brands$5.01+0.6%$5.94$3.51▼$23.20$583.92M1.884.34 million shs3.77 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%-0.92%-4.42%+15.51%+193.88%RLMDRelmada Therapeutics0.00%+11.76%-3.62%+7.61%+849.73%SPROSpero Therapeutics0.00%+1.06%+2.15%+10.04%+0.71%TLRYTilray Brands0.00%+0.81%-6.39%-27.83%+23.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50163.76% UpsideRLMDRelmada Therapeutics 2.71Moderate Buy$12.0088.38% UpsideSPROSpero Therapeutics 1.50ReduceN/AN/ATLRYTilray Brands 2.25Hold$11.50129.54% UpsideCurrent Analyst Ratings BreakdownLatest SPRO, TLRY, RLMD, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/13/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/29/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.004/21/2026SPROSpero Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026ACRSAclaris Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.004/16/2026ACRSAclaris Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M77.77N/AN/A$0.85 per share5.13RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ASPROSpero Therapeutics$66.80M2.52$0.16 per share18.73$1.05 per share2.77TLRYTilray Brands$821.31M0.71$1.45 per share3.45$14.04 per share0.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)RLMDRelmada Therapeutics-$57.38M-$1.09N/AN/AN/AN/A-71.22%-64.46%8/6/2026 (Estimated)SPROSpero Therapeutics$8.57M$0.2412.13N/AN/A24.90%35.58%24.95%8/11/2026 (Estimated)TLRYTilray Brands-$2.19B-$13.65N/AN/AN/A-156.51%-3.31%-2.42%7/27/2026 (Estimated)Latest SPRO, TLRY, RLMD, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026SPROSpero Therapeutics-$0.18-$0.13+$0.05-$0.13$0.26 million$0.26 million5/12/2026Q1 2026RLMDRelmada Therapeutics-$0.18-$0.22-$0.04-$0.22N/AN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million4/1/2026Q3 2026TLRYTilray Brands-$0.14-$0.24-$0.10-$0.24$201.35 million$206.73 million3/26/2026Q4 2025SPROSpero Therapeutics-$0.20$0.53+$0.73$0.53$26.00 million$41.30 million3/19/2026Q4 2025RLMDRelmada Therapeutics-$0.14-$0.27-$0.13-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03RLMDRelmada TherapeuticsN/A18.2518.25SPROSpero TherapeuticsN/A10.5010.50TLRYTilray Brands0.192.791.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%RLMDRelmada Therapeutics45.24%SPROSpero Therapeutics25.60%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%RLMDRelmada Therapeutics14.50%SPROSpero Therapeutics2.90%TLRYTilray Brands0.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableRLMDRelmada Therapeutics10104.89 million89.68 millionOptionableSPROSpero Therapeutics15057.90 million56.22 millionOptionableTLRYTilray Brands2,842116.55 million115.57 millionOptionableSPRO, TLRY, RLMD, and ACRS HeadlinesRecent News About These Companies10 Barrel Brewing and Pub Beer Kick Off Pacific Northwest Summer of Soccer Celebration3 hours ago | finance.yahoo.comWeekly Roundup on the Cannabis Sector & Psychedelic Sector3 hours ago | finance.yahoo.com10 Barrel Brewing and Pub Beer Kick Off Pacific Northwest Summer of Soccer CelebrationJune 15 at 7:51 AM | financialpost.comF10 Barrel Brewing and Pub Beer Kick Off Pacific Northwest Summer of Soccer CelebrationJune 15 at 7:30 AM | globenewswire.comShock Top Kicks Off the World’s Biggest Summer of Soccer with Shocking UpsetsJune 15 at 7:24 AM | finance.yahoo.comShock Top Kicks Off the World’s Biggest Summer of Soccer with Shocking UpsetsJune 15 at 7:11 AM | financialpost.comFShock Top Kicks Off the World's Biggest Summer of Soccer with Shocking UpsetsJune 15 at 7:00 AM | globenewswire.comTilray Is Growing 73% Internationally. The Market Is Paying Almost No Attention.June 14 at 1:15 PM | fool.comTop Cannabis Stocks To Watch Today - June 10thJune 13 at 4:07 AM | americanbankingnews.comBetter Marijuana Stock to Buy Right Now: Tilray or Trulieve?June 12 at 8:59 AM | fool.comTilray Brands (NASDAQ:TLRY) Trading 2% Higher - Still a Buy?June 11, 2026 | marketbeat.comBrewDog Rolls Back Pint Prices to £2 Across Scotland for 72-Hour Bank Holiday Weekend, Celebrating the National Team’s ReturnJune 11, 2026 | finance.yahoo.comBrewDog Rolls Back Pint Prices to £2 Across Scotland for 72-Hour Bank Holiday Weekend, Celebrating the National Team's ReturnJune 11, 2026 | globenewswire.comTilray Brands (NASDAQ:TLRY) Shares Down 2.9% - Time to Sell?June 10, 2026 | marketbeat.comTilray brings US craft beer brands to UK through BrewDogJune 10, 2026 | just-drinks.comJTilray Medical Germany Launches ARX™, a New Premium Medical Cannabis Brand Cultivated in GermanyJune 10, 2026 | finance.yahoo.comFresh From the U.S., BrewDog Unleashes Iconic American Craft Beers Across the U.K.June 10, 2026 | finance.yahoo.comThis US Cannabis Giant Is Launching Its First Premium Offering In Germany – Why It Matters?June 10, 2026 | stocktwits.comSFresh From the U.S., BrewDog Unleashes Iconic American Craft Beers Across the U.K.June 10, 2026 | financialpost.comFFresh From the U.S., BrewDog Unleashes Iconic American Craft Beers Across the U.K.June 10, 2026 | globenewswire.comTilray Medical Germany Launches ARX™, a New Premium Medical Cannabis Brand Cultivated in GermanyJune 10, 2026 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPRO, TLRY, RLMD, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.36 +0.04 (+0.93%) Closing price 04:00 PM EasternExtended Trading$4.36 +0.00 (+0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Relmada Therapeutics NASDAQ:RLMD$6.37 -0.28 (-4.21%) Closing price 04:00 PM EasternExtended Trading$6.34 -0.03 (-0.53%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Spero Therapeutics NASDAQ:SPRO$2.91 +0.06 (+2.11%) Closing price 04:00 PM EasternExtended Trading$2.93 +0.02 (+0.79%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Tilray Brands NASDAQ:TLRY$5.01 +0.03 (+0.60%) Closing price 04:00 PM EasternExtended Trading$5.00 -0.01 (-0.30%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
